NCT07400536RecruitingPhase 3
A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT
A Phase III, Multicenter, Open-label, Randomized Controlled Clinical Study on the Treatment of Locally Advanced Cervical Cancer With Cadonilimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy
Source: ClinicalTrials.gov · Last updated 13 May 2026
Brief summary (registry, in English)
This study mainly evaluated the efficacy and safety of Cadonilimab combined with chemotherapy followed by concurrent chemoradiotherapy versus standard concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 378 (estimated)
- First submitted
- 2 Feb 2026
- Start date
- Apr 2026
- Primary completion date
- Jul 2028
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Diseases
- Cervical cancer
- NCT number
- NCT07400536
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 378
- From Apr 2026 to the primary completion date, Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Had received any previous antineoplastic therapy, including but not limited to surgery (except biopsy), radiotherapy, or systemic therapy (chemotherapy, immunotherapy, targeted therapy);
Other illness
- Distant metastatic disease (including inguinal lymph node metastasis and lymph node metastasis above the level of the superior edge of the L1 pyramid in the proximal cephalic region, according to FIGO 2018 stage IVB);
- Had any condition that was deemed by other investigators to be ineligible for participation in the trial.
Other
- Subjects were excluded from the study if they met any of the following criteria:
- He had undergone total hysterectomy (removal of the corpus uteri and cervix);
- Inability to undergo brachytherapy or refusal to undergo brachytherapy for reasons such as anatomical abnormalities;
Who the study is looking for
- To be enrolled, subjects had to meet all of the following criteria:
- Female, aged 18-70 years (inclusive of cutoff values);
- Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix;
- Patients with stage IIB-IVA cervical cancer (FIGO stage 2018) who had not received any previous antineoplastic therapy;
- At least one measurable lesion according to RECIST v1.1;
- Eastern Cooperative Oncology Group (ECOG) performance-status score 0-1;
- Have adequate organ function.
Age in the registry: 18 years to 70 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.